First, the phase 3 trial of Moderna’s norovirus vaccine had to endure a clinical hold. | First, the phase 3 trial of ...

Entered into an exclusive license agreement with Dynavax for the Company’s COVID-19 oral pill vaccine candidate for potential cumulative proceeds ...

Q3 2025 Earnings Call Transcript November 13, 2025 Vaxart, Inc. beats earnings expectations. Reported EPS is $-0.04, ...

Vaxart Inc (VXRT) announces a major partnership with Dynavax and reports significant revenue growth, while navigating market ...

Vaxart secures major Dynavax deal, extending cash runway to 2027. Get Q3 earnings insights, clinical progress, and outlook on innovative oral vaccines.

Moderna’s nearly $20 billion cash hoard has dwindled to a single-digit stash. Following a series of setbacks for the biotech, ...

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected ...

Outbreaks of norovirus, an extremely contagious stomach bug, can spread quickly. “‘Tis the season for germs,” said Dr.

It's that time of year again, when winter bugs seem to be everywhere and if your child is at school or nursery and in close ...

Received FDA IND clearance to evaluate CDI-988 as both norovirus preventive and treatmentExpects to initiate CDI-988 Phase 1b ...